clinical trial · NCT06250205
Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
NewAmsterdam Pharma·phase1·completed·n = 30
Healthy VolunteersObicetrapibObicetrapib + Drospirenone / Ethinyl Estradiol (COC)Drospirenone / Ethinyl Estradiol (COC)
brief summary
A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.
started
Feb 5, 2024
primary completion
Apr 25, 2024
completion
Apr 26, 2024
last updated
Sep 19, 2024
detailed description
This is an interventional, drug-drug interaction study to evaluate the effect of daily doses of Obicetrapib tablets on the pharmacokinetics of a combined oral contraceptive (COC), Drospirenone and Ethinyl Estradiol.
official title
A Study to Evaluate the Effect of Daily Doses of Obicetrapib Tablets on the Pharmacokinetics of Drospirenone and Ethinyl Estradiol in Healthy Adult Female Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol